Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study

BACKGROUND: This study aimed to compare the efficacy of abiraterone acetate (AA) versus docetaxel (T) as first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) patients with or without the ineligible factors of the COU-AA-302 study (presence of visceral metastase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Prostate Int
Main Authors: Poon, Darren M.C., Chan, Kuen, Lee, Siu H., Chan, Tim W., Sze, Henry, Lee, Eric K.C., Lam, Daisy, Chan, Michelle F.T.
Formato: Artigo
Idioma:Inglês
Publicado em: Asian Pacific Prostate Society 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5857184/
https://ncbi.nlm.nih.gov/pubmed/29556486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.prnil.2017.08.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
A carregar...

Registos relacionados